Ultragenyx to Host Conference Call for First Quarter 2025 Financial Results and Corporate UpdateGlobeNewsWire • 04/30/25
Ultragenyx (RARE) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 ReleaseZacks Investment Research • 04/24/25
Ultragenyx (RARE) Soars 9.2%: Is Further Upside Left in the Stock?Zacks Investment Research • 04/10/25
Ultragenyx (RARE) Q4 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 02/13/25
Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate UpdateGlobeNewsWire • 02/13/25
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate UpdateGlobeNewsWire • 02/06/25
Ultragenyx Announces New Data Demonstrating that Treatment with UX111 AAV Gene Therapy Significantly Improved Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome Type A (MPS IIIA) Correlated with Sustained Reductions in CSF-HSGlobeNewsWire • 02/05/25
Ultragenyx's Multiple Commercial Assets And Candidates Impress Analyst; Sees Solid UpsideBenzinga • 01/15/25
Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 MilestonesGlobeNewsWire • 01/12/25
RARE's Cholesterol Drug Evkeeza Gains EC Approval for Expanded UseZacks Investment Research • 01/07/25
European Commission (EC) Extends the Approval of Evkeeza® (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH)GlobeNewsWire • 01/06/25
NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolaemia (HoFH)GlobeNewsWire • 12/20/24
Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman SyndromeGlobeNewsWire • 12/19/24
Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST's 17th Annual Global Science SummitGlobeNewsWire • 11/09/24
Ultragenyx Q3 Loss Narrower Than Expected, Revenues Beat EstimatesZacks Investment Research • 11/06/24